"In our view, MG01CI could have a best- in-class efficacy profile for treatment of PI-ADHD, which comprises over 40% of all ADHD sufferers," analyst Raghuram Selvaraju says, adding that the Orphan Designation in FXS "confers seven years of automatic market exclusivity and a rapid path to commercialization on MG01CI early in its development process as an FXS drug."
Price target is $40, which represents upside of 122% from Tuesday's close.
For more on MG01CI in FXS, see here.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs